Lori Winkler Sells 1,500 Shares of Zimmer Biomet (NYSE:ZBH) Stock

Key Points

• Lori Winkler, SVP of Zimmer Biomet, sold 1,500 shares of the company's stock for a total of $156,225, decreasing her position by 18% to 6,833 shares.
• Zimmer Biomet reported a 7% year-over-year increase in quarterly revenue, achieving $2.08 billion and EPS of $2.07, exceeding estimates.
• The company declared a quarterly dividend of $0.24 per share, with a yield of 0.9%, set to be paid on October 31st.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) SVP Lori Winkler sold 1,500 shares of the company's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares of the company's stock, valued at $711,656.95. This represents a 18.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Zimmer Biomet Stock Performance

NYSE ZBH traded down $1.52 during trading hours on Wednesday, hitting $102.33. The company had a trading volume of 1,576,823 shares, compared to its average volume of 1,998,362. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The company has a market cap of $20.27 billion, a PE ratio of 24.90, a price-to-earnings-growth ratio of 2.06 and a beta of 0.68. The business has a 50 day moving average of $98.89 and a 200-day moving average of $99.61.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The company had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the prior year, the firm posted $2.01 earnings per share. Zimmer Biomet's revenue for the quarter was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet's dividend payout ratio is currently 23.36%.

Institutional Trading of Zimmer Biomet

Institutional investors have recently made changes to their positions in the stock. Osaic Holdings Inc. increased its stake in shares of Zimmer Biomet by 13.0% during the 2nd quarter. Osaic Holdings Inc. now owns 25,553 shares of the medical equipment provider's stock worth $2,351,000 after purchasing an additional 2,949 shares during the last quarter. Orion Porfolio Solutions LLC acquired a new stake in Zimmer Biomet in the 2nd quarter worth $426,000. Thrivent Financial for Lutherans lifted its holdings in shares of Zimmer Biomet by 8.6% during the 2nd quarter. Thrivent Financial for Lutherans now owns 911,774 shares of the medical equipment provider's stock worth $83,163,000 after acquiring an additional 72,326 shares during the period. Monarch Capital Management Inc. lifted its holdings in shares of Zimmer Biomet by 2.0% during the 2nd quarter. Monarch Capital Management Inc. now owns 35,028 shares of the medical equipment provider's stock worth $3,201,000 after acquiring an additional 695 shares during the period. Finally, State of Wyoming bought a new position in shares of Zimmer Biomet during the 2nd quarter worth about $124,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Evercore ISI cut their price target on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Raymond James Financial raised their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Roth Capital reiterated a "buy" rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Royal Bank Of Canada lifted their price target on shares of Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Finally, UBS Group raised their target price on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a research note on Friday, August 8th. Nine research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Zimmer Biomet has an average rating of "Hold" and an average target price of $111.00.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.